Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase

Gabriele Fragasso, Roberto Spoladore, Amarild Cuko, Altin Palloshi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the heart. Pharmacological agents that directly inhibit fatty acid oxidation include inhibitors of 3-ketoacyl coenzyme A thiolase (3-KAT), the last enzyme involved in ß-oxidation. The most extensively investigated agents of this group of drugs are trimetazidine and ranolazine. Clinical studies have shown that these agents can substantially increase the ischemic threshold in patients with effort angina. However, the results of current research is also supporting the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism by 3-KAT inhibitors could be an effective adjunctive treatment in patients with heart failure, in terms of left ventricular function and glucose metabolism improvement. In fact, these agents have also been shown to improve overall glucose metabolism in diabetic patients with left ventricular dysfunction. In this paper, the recent literature on the beneficial effects of this new class of drugs on left ventricular dysfunction and glucose metabolism is reviewed and discussed.

Original languageEnglish
Pages (from-to)190-196
Number of pages7
JournalCurrent Clinical Pharmacology
Volume2
Issue number3
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Coenzymes
Fatty Acids
Heart Failure
Pharmacology
Glucose
Left Ventricular Dysfunction
Coenzyme A
Trimetazidine
Left Ventricular Function
Pharmaceutical Preparations
Energy Metabolism
Enzymes
Research

Keywords

  • 3-ketoacyl coenzyme A thiolase inhibitors
  • Diabetes
  • Heart failure
  • Left ventricular function
  • Ranolazine
  • Trimetazidine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase. / Fragasso, Gabriele; Spoladore, Roberto; Cuko, Amarild; Palloshi, Altin.

In: Current Clinical Pharmacology, Vol. 2, No. 3, 09.2007, p. 190-196.

Research output: Contribution to journalArticle

@article{7d8d3af2be984de789f85347235e306e,
title = "Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase",
abstract = "A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the heart. Pharmacological agents that directly inhibit fatty acid oxidation include inhibitors of 3-ketoacyl coenzyme A thiolase (3-KAT), the last enzyme involved in {\ss}-oxidation. The most extensively investigated agents of this group of drugs are trimetazidine and ranolazine. Clinical studies have shown that these agents can substantially increase the ischemic threshold in patients with effort angina. However, the results of current research is also supporting the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism by 3-KAT inhibitors could be an effective adjunctive treatment in patients with heart failure, in terms of left ventricular function and glucose metabolism improvement. In fact, these agents have also been shown to improve overall glucose metabolism in diabetic patients with left ventricular dysfunction. In this paper, the recent literature on the beneficial effects of this new class of drugs on left ventricular dysfunction and glucose metabolism is reviewed and discussed.",
keywords = "3-ketoacyl coenzyme A thiolase inhibitors, Diabetes, Heart failure, Left ventricular function, Ranolazine, Trimetazidine",
author = "Gabriele Fragasso and Roberto Spoladore and Amarild Cuko and Altin Palloshi",
year = "2007",
month = "9",
doi = "10.2174/157488407781668776",
language = "English",
volume = "2",
pages = "190--196",
journal = "Current Clinical Pharmacology",
issn = "1574-8847",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase

AU - Fragasso, Gabriele

AU - Spoladore, Roberto

AU - Cuko, Amarild

AU - Palloshi, Altin

PY - 2007/9

Y1 - 2007/9

N2 - A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the heart. Pharmacological agents that directly inhibit fatty acid oxidation include inhibitors of 3-ketoacyl coenzyme A thiolase (3-KAT), the last enzyme involved in ß-oxidation. The most extensively investigated agents of this group of drugs are trimetazidine and ranolazine. Clinical studies have shown that these agents can substantially increase the ischemic threshold in patients with effort angina. However, the results of current research is also supporting the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism by 3-KAT inhibitors could be an effective adjunctive treatment in patients with heart failure, in terms of left ventricular function and glucose metabolism improvement. In fact, these agents have also been shown to improve overall glucose metabolism in diabetic patients with left ventricular dysfunction. In this paper, the recent literature on the beneficial effects of this new class of drugs on left ventricular dysfunction and glucose metabolism is reviewed and discussed.

AB - A direct approach to manipulate cardiac energy metabolism consists in modifying substrate utilization by the heart. Pharmacological agents that directly inhibit fatty acid oxidation include inhibitors of 3-ketoacyl coenzyme A thiolase (3-KAT), the last enzyme involved in ß-oxidation. The most extensively investigated agents of this group of drugs are trimetazidine and ranolazine. Clinical studies have shown that these agents can substantially increase the ischemic threshold in patients with effort angina. However, the results of current research is also supporting the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism by 3-KAT inhibitors could be an effective adjunctive treatment in patients with heart failure, in terms of left ventricular function and glucose metabolism improvement. In fact, these agents have also been shown to improve overall glucose metabolism in diabetic patients with left ventricular dysfunction. In this paper, the recent literature on the beneficial effects of this new class of drugs on left ventricular dysfunction and glucose metabolism is reviewed and discussed.

KW - 3-ketoacyl coenzyme A thiolase inhibitors

KW - Diabetes

KW - Heart failure

KW - Left ventricular function

KW - Ranolazine

KW - Trimetazidine

UR - http://www.scopus.com/inward/record.url?scp=34948849728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948849728&partnerID=8YFLogxK

U2 - 10.2174/157488407781668776

DO - 10.2174/157488407781668776

M3 - Article

C2 - 18690865

AN - SCOPUS:34948849728

VL - 2

SP - 190

EP - 196

JO - Current Clinical Pharmacology

JF - Current Clinical Pharmacology

SN - 1574-8847

IS - 3

ER -